Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 236

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 236
---
 Maxim Group LLC (“Maxim”) to discuss potential PIPE transactions to be explored
in connect with the proposed business combination.

In late July and
early August 2024, Longevity, FutureTech, Nelson Mullins and Moses Singer continued to negotiate and draft the merger agreement and proposed
amendments to the combination and exchange agreements to be entered into in connection with the proposed business combination.

| 117 |

On August 7, 2024,
the proposed amendments to the combination and exchange agreements to be entered into in connection with the proposed business combination
were sent to Cerevast and Aegeria for review. On August 8, 2024, the proposed amendments to the combination and exchange agreements were
executed by the parties, and Longevity notified Novokera that it was terminating the Novokera C&E Agreement pursuant to Section 10.1(b)
due to multiple closing conditions not occurring or being waived as of the Outside Date.

On August 8, 2024, the FutureTech
Board requested Mr. Wang to recuse himself from all future FutureTech Board meetings related to Longevity and held a meeting, excluding
Mr. Wang, and to re-evaluate financial models and all materials information regarding Longevity and approved measures to clear
the conflicts of interest arising from Mr. Wang’s prior involvement with the Sponsor and Longevity as well as the Sponsor’s
affiliate’s loans to Longevity. These measures included:

1. Conduct
due diligence on each director to identify any conflict of interest related to Longevity merger;

2. Create
a Longevity Acquisition Committee within the FutureTech Board consisting solely of directors who have no conflict of interest;

3. Ratify the replacement
Nelson Mullins, who was legal counsel to both Longevity and FutureTech, with new legal counsel, Moses Singer; and

4. Ratify
the engagement of NewBridge for conducting a valuation of Longevity, among other things, and to render a fairness opinion regarding the
acquisition of Longevity.

The above measures were unanimously
approved by the Board. As a result, FutureTech’s Longevity Acquisition Committee of the Board consists of all directors except
Mr. Wang, and Mr. Wang was also removed from all involvement in the Sponsor.

In August 2024
and September 2024, Longevity, FutureTech, Nelson Mullins and Moses Singer continued to negotiate and draft the merger agreement to be
entered into in connection with the proposed business combination, including all ancillary agreements